NovoCure Ltd — Director's Dealing 2019

Jan 16, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2019-01-14

Reporting Person: Danziger Asaf (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-14	Ordinary Shares	M	100000	$3.44	Acquired	271164	Direct
2019-01-14	Ordinary Shares	S	100000	$43.524	Disposed	171164	Direct
2019-01-15	Ordinary Shares	M	100000	$3.44	Acquired	271164	Direct
2019-01-15	Ordinary Shares	S	100000	$43.488	Disposed	171164	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-14	Options to Buy Ordinary Shares	$3.44	M	100000	Disposed	2021-12-13	Ordinary Shares (100000)	Direct
2019-01-15	Options to Buy Ordinary Shares	$3.44	M	100000	Disposed	2021-12-13	Ordinary Shares (100000)	Direct

Footnotes

F1: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.

F2: On January 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 100,000 shares in multiple trades at prices ranging from $43.44 to $43.66. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: On January 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 100,000 shares in multiple trades at prices ranging from $43.44 to $43.92. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

F4: Fully vested and currently exercisable as of the date hereof.